Unexpected Low Rate of Amyloid-β Pathology in Multiple Sclerosis Patients

The life expectancy of people with multiple sclerosis (MS) has increased, yet we have noted that development of a typical Alzheimer disease dementia syndrome is uncommon. We hypothesized that Alzheimer disease pathology is uncommon in MS patients. In 100 MS patients, the rate of amyloid-β plasma bio...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of neurology 2024-09, Vol.96 (3), p.453-459
Hauptverfasser: Brier, Matthew R, Schindler, Suzanne E, Salter, Amber, Perantie, Dana, Shelley, Nicole, Judge, Bradley, Keefe, Sarah, Kirmess, Kristopher M, Verghese, Philip B, Yarasheski, Kevin E, Venkatesh, Venky, Raji, Cyrus A, Gordon, Brian A, Bateman, Randall J, Morris, John C, Naismith, Robert T, Holtzman, David M, Benzinger, Tammie L S, Cross, Anne H
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The life expectancy of people with multiple sclerosis (MS) has increased, yet we have noted that development of a typical Alzheimer disease dementia syndrome is uncommon. We hypothesized that Alzheimer disease pathology is uncommon in MS patients. In 100 MS patients, the rate of amyloid-β plasma biomarker positivity was approximately half the rate in 300 non-MS controls matched on age, sex, apolipoprotein E proteotype, and cognitive status. Interestingly, most MS patients who did have amyloid-β pathology had features atypical for MS at diagnosis. These results support that MS is associated with reduced Alzheimer disease risk, and suggest new avenues of research. ANN NEUROL 2024;96:453-459.
ISSN:0364-5134
1531-8249
1531-8249
DOI:10.1002/ana.27027